公司回答表示：您好，公司通过在国外成立子公司，组建国外业务部门，引入有国际业务经验的人才， 积极拓展国外临床业务。感谢您的关注！ 金融界8月13日消息，有投资者在互动平台向博济医药提问：公司有没有在积极拓展国外市场？ ...

Core Insights - The CXO (Contract Research Organization and Contract Development and Manufacturing Organization) sector in A-shares shows a mixed performance in the first half of the year, with 19 out of 35 companies reporting a year-on-year profit increase, indicating a positive trend in the industry [1] Group 1: Company Performance - WuXi AppTec leads the CXO companies with a net profit of 5.313 billion yuan, followed by Kelun Pharmaceutical with 1.686 billion yuan, and Tigermed with 1.388 billion yuan [2] - WuXi AppTec's revenue reached 18.871 billion yuan, a year-on-year increase of 6.28%, with a net profit growth of 14.61% [2] - Kelun Pharmaceutical reported a revenue of 4.622 billion yuan, a decline of 8.33%, and a net profit decrease of 3.09% [3] Group 2: Sector Trends - The demand for peptide drugs, traditional Chinese medicine, and ADC (Antibody-Drug Conjugates) is increasing, leading to significant order growth for some CXO companies [4] - WuXi AppTec's TIDES business, focusing on oligonucleotides and peptides, generated 1.33 billion yuan in revenue, a growth of 37.9%, with a backlog of orders increasing by 188% [4] - The CRO service provider Boji Pharmaceutical reported a 49% increase in new business contracts, with traditional Chinese medicine contracts growing by approximately 400% [4] Group 3: Market Expansion - Despite a cooling investment environment in the global pharmaceutical sector, several CXO companies are experiencing growth in overseas markets [5] - Kelun Pharmaceutical's revenue from U.S. clients reached 3.348 billion yuan, with a 44.77% increase when excluding large orders [5] - Tigermed's revenue was 3.711 billion yuan, a year-on-year increase of 3.25%, with a net profit growth of 16.47% [6]

Core Viewpoint - The listing process of Jiangxi Shimei Pharmaceutical Co., Ltd. has attracted significant attention, particularly regarding its business focus and financial performance, as it primarily generates revenue from generic drugs while its innovative drugs are still in the research phase [1][2][3]. Business and Industry Situation - Jiangxi Shimei Pharmaceutical, established in November 2002, focuses on the research, development, production, and sales of generic drugs, improved innovative drugs, and innovative drugs, while also providing comprehensive services such as technology transfer and contract development and manufacturing (CDMO) [2][3]. - The company plans to raise 608 million yuan for projects related to the development and industrialization of chiral antihypertensive drugs, innovative drug research in Shandong, and the establishment of a formulation production base [2]. Performance Trends - The company reported significant revenue growth during the reporting period, with revenues of 81 million yuan, 148 million yuan, 184 million yuan, and 192 million yuan from 2020 to 2023, reflecting year-on-year growth rates of 81.72% and 24.53% in 2021 and 2022, respectively [4]. - Net profits also increased substantially, with figures of 19.31 million yuan, 51.54 million yuan, 75.58 million yuan, and 99.58 million yuan, showing year-on-year growth of 166.89% and 46.66% in 2021 and 2022, respectively [4]. Comparison with Peers - While Jiangxi Shimei Pharmaceutical's performance has improved, some of its peers, such as Boji Pharmaceutical and Baihua Pharmaceutical, have experienced declines in net profit, raising regulatory concerns about the reasons behind these contrasting trends [5]. - The company attributes its growth to favorable industry policies, strong market demand, and successful project registrations with large pharmaceutical enterprises, which have positively impacted its revenue [5]. Gross Margin Analysis - The gross margin of Jiangxi Shimei Pharmaceutical has consistently exceeded industry averages, with figures of 80.22%, 81.79%, 83.63%, and 88.28% during the reporting period [6]. - The gross margin for its pharmaceutical research and CDMO business was reported at 67.38%, 81.60%, 90.58%, and 91.84%, significantly higher than the average gross margins of comparable companies [6][7]. - The company’s gross margin is also notably higher than leading CRO firms like WuXi AppTec, which reported gross margins of 37.97% to 40.52% during the same period, indicating a strong competitive position [7].

Group 1: Company Performance - Viking Therapeutics' stock surged by 121.02% to a record high of $85.05 per share, driven by positive clinical trial data for weight loss drug VK2735 [1] - Over the past two years, Viking Therapeutics has seen a cumulative increase of 23.8 times, significantly outperforming major competitors Eli Lilly and Novo Nordisk, which increased by 2.11 times and 1.43 times respectively [1] - The Phase II clinical trial results for VK2735 showed that participants lost an average of 14.6 kg over 13 weeks, with 88% of patients achieving a weight loss of over 10% [1][2] Group 2: Market Potential - The global weight loss market for prescription drugs is projected to exceed $77 billion by 2030, with a compound annual growth rate (CAGR) of 36% from 2024 to 2030 [3] - By 2030, the global annual sales of GLP-1 class drugs are expected to reach $100 billion [3] Group 3: Clinical Developments - Viking Therapeutics plans to advance VK2735 into further clinical development later this year and is also set to report Phase I data for the oral formulation of VK2735 [2] - Several A-share companies are making progress in the weight loss drug sector, with over 40 stocks involved in this market [3] - Companies like Zhongsheng Pharmaceutical and Hanyu Pharmaceutical are actively conducting clinical trials for their respective weight loss and diabetes treatments [4][5] Group 4: Market Sentiment - The weight loss drug concept stocks have shown a rebound since the beginning of the year, with several stocks reporting positive year-to-date performance [6] - Despite some stocks experiencing significant pullbacks, 35 concept stocks have received "positive" ratings from institutions, indicating strong market interest [7]

天眼查商业履历信息显示，博济医药科技股份有限公司，成立于2002年，位于广州市，是一家以从事研 究和试验发展为主的企业。企业注册资本38198.9708万人民币，实缴资本10000万人民币。公司法定代 表人为王廷春。 通过天眼查大数据分析，博济医药科技股份有限公司共对外投资了39家企业，参与招投标项目112次， 知识产权方面有商标信息49条，专利信息47条，此外企业还拥有行政许可44个。 金融界消息 截至2025年8月11日收盘，博济医药（300404）报收于11.0元，上涨1.38%，换手率6.71%， 成交量18.84万手，成交金额2.06亿元。 资金流向方面，今日主力资金净流出1136.01万元，占比成交额5.51%。其中，超大单净流出132.40万 元、占成交额0.64%，大单净流出1003.60万元、占成交额4.87%，中单净流出流出661.63万元、占成交 额3.21%，小单净流入1797.64万元、占成交额8.73%。 博济医药最新一期业绩显示，截至2025一季报，公司营业总收入1.39亿元、同比减少17.06%，归属净利 润390.06万元，同比减少76.38%，扣非净利润169.79万元，同 ...

Group 1 - The core viewpoint is that Boji Pharmaceutical (300404) is one of the few CRO companies capable of providing integrated services for traditional Chinese medicine (TCM) research and development [1] - The company's TCM business has experienced rapid growth in recent years, with steady increases in service projects, orders, and revenue [1] - The increasing emphasis from the government on the TCM industry is expected to create new development opportunities for the sector [1]

Core Viewpoint - The company, Boji Pharmaceutical, is primarily focused on innovative drug development, with a diverse portfolio that includes chemical drugs, biological drugs, and traditional Chinese medicine [1] Group 1: Drug Development - The company has completed Phase III clinical trials and launched innovative drugs such as recombinant human albumin injection (from rice) and sildenafil hydrochloride tablets [1] - A self-developed traditional Chinese medicine new drug (Category 1.1) has completed Phase III clinical trials, while a collaborative development project in the same category is currently in Phase III [1] Group 2: Research and Technology - The company has established databases related to researchers, clinical trial institutions, and clinical trial projects to enhance its research capabilities [1] - The company is actively exploring the application of AI technology in drug development to improve efficiency and quality, with current usage in both preclinical and clinical operations [1]

Core Insights - The company, Boji Pharmaceutical, focuses on innovative drug development, with a diverse portfolio including chemical drugs, biological drugs, and traditional Chinese medicine [1] - The company has successfully completed Phase III clinical trials and launched innovative drugs such as recombinant human albumin injection and sildenafil citrate tablets [1] - The company is actively exploring the application of AI technology in drug development to enhance efficiency and quality, with ongoing use in both preclinical and clinical operations [1] Group 1 - The company has numerous projects in service, primarily centered on innovative drugs [1] - The company has completed Phase III clinical trials for several innovative drugs and has a traditional Chinese medicine new drug in Phase III clinical trials [1] - The company has established databases related to researchers, clinical trial institutions, and clinical trial projects [1] Group 2 - The company is transferring its self-developed projects to external clients after achieving certain technical results, allowing clients to continue development [1] - The company is exploring more applications of AI technology in drug development beyond current uses [1] - The company is preparing to establish a real-world database for AI models to enhance innovative drug clinical research [3]

Core Insights - Guangzhou Development Zone has a total of 88 listed companies, accounting for one-third of the total number and market capitalization of listed companies in Guangzhou, ranking first in the city and among national economic development zones [1][2] - The zone has cultivated nearly 400 pre-listing enterprises and has 12 companies in the filing and review stages [1] - A modern financial investment and financing service system named "12345" has been established, which includes a policy system, two cultivation projects, three service mechanisms, four service carriers, and five activity brands [1][2] Financial Services and Support Mechanisms - The "12345" modern financial investment and financing service system aims to guide financial resources towards small and micro enterprises, technological innovation, and green development [2] - The two cultivation projects focus on pre-listing nurturing and post-listing high-quality development training to enhance corporate governance and leverage capital markets for growth [2] - Three service mechanisms include the establishment of a science and technology innovation fund, a risk compensation mechanism for inclusive loans, and an optimized enterprise financing credit enhancement mechanism [2] Investment in Biomedicine - Guangzhou High-tech Zone Investment Group has established over 20 specialized funds in biomedicine, with a total subscribed scale exceeding 250 billion, successfully investing in 101 quality biomedicine and health enterprises [3] - New funds are being set up, including a 30 million yuan fund for ophthalmology transformation and a 6 billion yuan fund focused on investment linkage and industrial finance integration [3] Comprehensive Service Solutions - Science City (Guangzhou) Investment Group provides a full-chain solution for urban construction and comprehensive operation services, covering approximately 5.7 million square meters of industrial space [3] - The group offers a comprehensive support plan for enterprises, including investment, financial services, and business application testing [3] Technology Financial Services - Guangzhou Development Zone Holding Group has built a "brokerage + financial services" full-chain service model to enhance technology financial services [4] - The company utilizes REITs and other capital operations to accelerate fund recovery, reinvesting in new park construction and attracting investments [4]

Core Viewpoint - The company, Boji Pharmaceutical (300404.SZ), is a specialized CRO service provider focused on offering outsourced pharmaceutical research and development services, currently not engaged in any projects related to Chikungunya virus disease [1] Group 1 - The company provides pharmaceutical R&D outsourcing services and charges technical service fees [1] - There are currently no ongoing projects related to Chikungunya virus disease [1]